Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M B Atkins

Showing results (41-50 of 101) with videos related to

Pageof 11
Sort By:
Journal of Immunological Methods|August 9, 1993
A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapyH Tilg, D Pape, E Trehu, et al.
European Radiology|December 6, 2001
Multiphase contrast-enhanced helical CT of liver metastases from renal cell carcinomaV D Raptopoulos, S P Blake, K Weisinger, et al.
Cytokine|March 1, 1994
Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humansH Tilg, E Trehu, L Shapiro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group studyC I Falkson, J Ibrahim, J M Kirkwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1991
Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot studyP A Demchak, J W Mier, N J Robert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical responseJ A Gollob, J W Mier, K Veenstra, et al.
The New England Journal of Medicine|June 16, 1988
Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cellsM B Atkins, J W Mier, D R Parkinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2001
A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanomaM B Atkins, B Redman, J Mier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancerM J Robertson, C Cameron, M B Atkins, et al.
Medical Oncology (Northwood, London, England)|March 29, 2002
Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokinesJ Dutcher, M B Atkins, K Margolin, et al.
Pageof 11

Showing results (41-50 of 101) with videos related to

Sort By:
Pageof 11
Journal of Immunological Methods|August 9, 1993
A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapyH Tilg, D Pape, E Trehu, et al.
European Radiology|December 6, 2001
Multiphase contrast-enhanced helical CT of liver metastases from renal cell carcinomaV D Raptopoulos, S P Blake, K Weisinger, et al.
Cytokine|March 1, 1994
Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humansH Tilg, E Trehu, L Shapiro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group studyC I Falkson, J Ibrahim, J M Kirkwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1991
Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot studyP A Demchak, J W Mier, N J Robert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical responseJ A Gollob, J W Mier, K Veenstra, et al.
The New England Journal of Medicine|June 16, 1988
Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cellsM B Atkins, J W Mier, D R Parkinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2001
A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanomaM B Atkins, B Redman, J Mier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancerM J Robertson, C Cameron, M B Atkins, et al.
Medical Oncology (Northwood, London, England)|March 29, 2002
Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokinesJ Dutcher, M B Atkins, K Margolin, et al.
Pageof 11